This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Betulinic Acid
- DrugBank Accession Number
- DB12480
- Background
Betulinic Acid has been used in trials studying the treatment of Dysplastic Nevus Syndrome.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Betulinic Acid (DB12480)
- Weight
- Average: 456.711
Monoisotopic: 456.360345406 - Chemical Formula
- C30H48O3
- Synonyms
- beta-betulinic acid
- External IDs
- ALS-357
- NSC-113090
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Betulinic Acid. Acemetacin The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Acemetacin. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Betulinic Acid. Alclofenac The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Alclofenac. Aminophenazone The risk or severity of adverse effects can be increased when Aminophenazone is combined with Betulinic Acid. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Retroviral Agents
- Antimalarials
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Antiparasitic Agents
- Antiprotozoals
- Antirheumatic Agents
- Antiviral Agents
- Hormone Antagonists
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Lupanes
- Non COX-2 selective NSAIDS
- Pentacyclic Triterpenes
- Peripheral Nervous System Agents
- Prostaglandin Antagonists
- Sensory System Agents
- Terpenes
- Triterpenes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as triterpenoids. These are terpene molecules containing six isoprene units.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Triterpenoids
- Direct Parent
- Triterpenoids
- Alternative Parents
- 18-hydroxysteroids / Oxosteroids / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- 18-hydroxysteroid / 18-oxosteroid / Alcohol / Aliphatic homopolycyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Cyclic alcohol / Hydrocarbon derivative / Hydroxysteroid
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- hydroxy monocarboxylic acid, pentacyclic triterpenoid (CHEBI:3087) / Lupanes (C08619) / Lupane triterpenoids (LMPR0106140004)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 4G6A18707N
- CAS number
- 472-15-1
- InChI Key
- QGJZLNKBHJESQX-FZFNOLFKSA-N
- InChI
- InChI=1S/C30H48O3/c1-18(2)19-10-15-30(25(32)33)17-16-28(6)20(24(19)30)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h19-24,31H,1,8-17H2,2-7H3,(H,32,33)/t19-,20+,21-,22+,23-,24+,27-,28+,29+,30-/m0/s1
- IUPAC Name
- (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-17-hydroxy-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0²,¹⁰.0⁵,⁹.0¹⁴,¹⁹]henicosane-5-carboxylic acid
- SMILES
- [H]OC(=O)[C@]12CC[C@@]([H])(C(C)=C)[C@]1([H])[C@@]1([H])CC[C@]3([H])[C@@]4(C)CC[C@]([H])(O[H])C(C)(C)[C@]4([H])CC[C@@]3(C)[C@]1(C)CC2
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0030094
- KEGG Compound
- C08619
- PubChem Compound
- 64971
- PubChem Substance
- 347828718
- ChemSpider
- 58496
- BindingDB
- 23208
- ChEBI
- 3087
- ChEMBL
- CHEMBL269277
- ZINC
- ZINC000004097714
- PDBe Ligand
- 06L
- PDB Entries
- 8gxp
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 1 Unknown Status Treatment Melanoma 1 1, 2 Withdrawn Treatment Dysplastic Nevus Syndrome 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Cutaneous Gel Topical 80 mg/g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000204 mg/mL ALOGPS logP 5.34 ALOGPS logP 6.64 Chemaxon logS -6.4 ALOGPS pKa (Strongest Acidic) 4.75 Chemaxon pKa (Strongest Basic) -0.84 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 57.53 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 132.63 m3·mol-1 Chemaxon Polarizability 54.64 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 218.972749 predictedDarkChem Lite v0.1.0 [M-H]- 195.10812 predictedDeepCCS 1.0 (2019) [M+H]+ 215.770749 predictedDarkChem Lite v0.1.0 [M+H]+ 196.93303 predictedDeepCCS 1.0 (2019) [M+Na]+ 216.167749 predictedDarkChem Lite v0.1.0 [M+Na]+ 202.84941 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:33 / Updated at January 14, 2023 19:03